Table 2.

Effects of combination treatment on inhibition of multi-azole-resistant TR₄₆/Y121F/T289A A. fumigatus invasion.

Compartment Treated		Days (% Inhibition)
Upper	Lower	1	2	3	4	5	6
PC945 (3 μg/mL)	DMSO	29.7 ± 2.05c	−0.16 ± 1.97	−3.12 ± 3.78	4.22 ± 1.78	−12.5 ± 2.99	4.64 ± 4.42
DMSO	Posaconazole (0.3 μg/mL)	98.1 ± 0.03c	81.4 ± 1.83c	26.9 ± 15.7	1.94 ± 1.16	−10.7 ± 4.73	5.94 ± 2.91
PC945 (3 μg/mL)	Posaconazole (0.3 μg/mL)	98.9 ± 0.20c	96.8 ± 0.44c	93.8 ± 1.04b	88.9 ± 4.67c	−7.38 ± 5.02	2.78 ± 5.05
	SRa	1.00 ± 0.00	1.19 ± 0.02	6.61 ± 3.45	43.2 ± 33.4	0.50 ± 0.00	1.00 ± 0.00
Posaconazole (3 μg/mL)	DMSO	99.1 ± 0.26c	97.2 ± 1.33c	93.6 ± 3.72c	52.1 ± 15.6b	−6.69 ± 5.22	5.78 ± 2.24
DMSO	Posaconazole (3 μg/mL)	99.8 ± 0.12c	99.9 ± 0.03c	99.9 ± 0.00c	99.9 ± 0.03c	99.8 ± 0.09c	7.32 ± 1.96
Posaconazole (3 μg/mL)	Posaconazole (3 μg/mL)	99.7 ± 0.13c	99.9 ± 0.03c	99.9 ± 0.03c	99.9 ± 0.03c	99.7 ± 0.03c	0.15 ± 1.60
	SRa	1.00 ± 0.00	1.00 ± 0.00	1.00 ± 0.00	1.00 ± 0.00	1.00 ± 0.00	0.07 ± 0.06
Voriconazole (10 μg/mL)	DMSO	−4.71 ± 0.90	1.57 ± 4.76	−0.99 ± 4.58	2.56 ± 2.10	−4.04 ± 0.33	1.78 ± 3.99
DMSO	Voriconazole (10 μg/mL)	16.1 ± 12.5	−1.32 ± 1.61	−1.23 ± 3.92	−4.06 ± 4.75	−6.01 ± 5.10	6.45 ± 3.96
Voriconazole (10 μg/mL)	Voriconazole (10 μg/mL)	23.1 ± 6.42	4.25 ± 2.80	−5.86 ± 2.90	−3.97 ± 2.07	−12.0 ± 1.58	5.31 ± 3.19
	SRa	17.9 ± 16.8	8.75 ± 8.28	0.18 ± 0.16	0.04 ± 0.01	0.41 ± 0.09	0.58 ± 0.19

N = 3 independent experiments, each experiment was conducted in duplicate.

^aSynergic Ratio (>1: Synergy), The value of 0.1 was applied for 0 or negative values to assist in the calculations.

^bp < 0.01, ^cp < 0.001 vs. infection control.